The Genetic Puzzle of Cerebral Palsy: Results of a Monocentric Study.

Cerebral palsy Chromosomal microarray Exome sequencing Functional enrichment analysis

Journal

Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183

Informations de publication

Date de publication:
05 Aug 2024
Historique:
received: 01 12 2023
revised: 03 06 2024
accepted: 30 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: aheadofprint

Résumé

Cerebral palsy (CP) is the most frequent cause of motor impairment in children. Although perinatal asphyxia was long considered to be the leading cause of CP, recent studies demonstrate its causation in only around one in 10 individuals with CP. Instead, genetic causes are increasingly demonstrated. We systematically performed clinical phenotyping and genetic investigations in a monocentric CP cohort, aiming to gain insight into the contribution of genetic variants in CP and its different subtypes. Chromosomal microarray and/or trio exome sequencing were systematically performed in 337 individuals with CP between September 2017 and August 2022. Deep phenotyping was performed through clinical multidisciplinary evaluation and review of medical files. Genetic analyses resulted in an overall diagnostic yield of 38.3% (129 of 337). In cases with one or more comorbidities (intellectual disability, epilepsy, autism spectrum disorder), the yield increased to almost 50%. Functional enrichment analysis showed over-representation of the following pathways: genetic imprinting, DNA modification, liposaccharide metabolic process, neuron projection guidance, and axon development. Genetic analyses in our CP cohort, the largest monocentric study to date, demonstrated a diagnostic yield of 38.3%, highlighting the importance of genetic testing in CP. The diagnosis of a genetic disorder is essential for prognosis and clinical follow-up, as well as for family counseling. Pathway analysis points to dysregulation of general developmental and metabolic processes as well as neuronal development and function. Unraveling the role of these pathways in CP pathogenesis is instrumental for the identification of CP candidate genes as well as potential therapeutic targets.

Sections du résumé

BACKGROUND BACKGROUND
Cerebral palsy (CP) is the most frequent cause of motor impairment in children. Although perinatal asphyxia was long considered to be the leading cause of CP, recent studies demonstrate its causation in only around one in 10 individuals with CP. Instead, genetic causes are increasingly demonstrated. We systematically performed clinical phenotyping and genetic investigations in a monocentric CP cohort, aiming to gain insight into the contribution of genetic variants in CP and its different subtypes.
METHODS METHODS
Chromosomal microarray and/or trio exome sequencing were systematically performed in 337 individuals with CP between September 2017 and August 2022. Deep phenotyping was performed through clinical multidisciplinary evaluation and review of medical files.
RESULTS RESULTS
Genetic analyses resulted in an overall diagnostic yield of 38.3% (129 of 337). In cases with one or more comorbidities (intellectual disability, epilepsy, autism spectrum disorder), the yield increased to almost 50%. Functional enrichment analysis showed over-representation of the following pathways: genetic imprinting, DNA modification, liposaccharide metabolic process, neuron projection guidance, and axon development.
CONCLUSIONS CONCLUSIONS
Genetic analyses in our CP cohort, the largest monocentric study to date, demonstrated a diagnostic yield of 38.3%, highlighting the importance of genetic testing in CP. The diagnosis of a genetic disorder is essential for prognosis and clinical follow-up, as well as for family counseling. Pathway analysis points to dysregulation of general developmental and metabolic processes as well as neuronal development and function. Unraveling the role of these pathways in CP pathogenesis is instrumental for the identification of CP candidate genes as well as potential therapeutic targets.

Identifiants

pubmed: 39213953
pii: S0887-8994(24)00284-4
doi: 10.1016/j.pediatrneurol.2024.07.019
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.

Auteurs

Liene Thys (L)

Department of Pediatric Neurology, Antwerp University Hospital/University of Antwerp, Edegem/Wilrijk, Belgium.

Diane Beysen (D)

Department of Pediatric Neurology, Antwerp University Hospital/University of Antwerp, Edegem/Wilrijk, Belgium.

Berten Ceulemans (B)

Department of Pediatric Neurology, Antwerp University Hospital/University of Antwerp, Edegem/Wilrijk, Belgium.

Sandra Kenis (S)

Department of Pediatric Neurology, Antwerp University Hospital/University of Antwerp, Edegem/Wilrijk, Belgium.

Charlotte Dielman (C)

Department of Pediatrics, Queen Paola Children's Hospital, Wilrijk, Belgium.

Filip Roelens (F)

Department of Pediatrics, AZ Delta Hospital, Roeselare, Belgium.

Edwin Reyniers (E)

Center of Medical Genetics, Antwerp University Hospital/University of Antwerp, Edegem/Wilrijk, Belgium.

Ligia Mateiu (L)

Center of Medical Genetics, Antwerp University Hospital/University of Antwerp, Edegem/Wilrijk, Belgium.

Katrien Janssens (K)

Center of Medical Genetics, Antwerp University Hospital/University of Antwerp, Edegem/Wilrijk, Belgium.

Marije Meuwissen (M)

Center of Medical Genetics, Antwerp University Hospital/University of Antwerp, Edegem/Wilrijk, Belgium. Electronic address: marije.meuwissen@uza.be.

Classifications MeSH